I'm doing research on the GLP-1 connection with papillary right now, because I see patients with thyroid cancer who have obesity and they're at high risk for recurrent thyroid cancer

CrossRef Studying serum immunoglobulin levels in metabolic dysfunction-associated steatotic liver disease Hazem Abosheaishaa, Emad Ahmad Awad Hussein, Shereen Abou Bakr Saleh, Mahmoud Nassar, Abdulaziz Elmaradny, Mohammed Abdelwahed, Amr Ali, Khaled Elfert, Ahmed Mohamed ElGhandour Egyptian Liver Journal .2026;[Epub] CrossRef Association Between Periodontitis and Metabolic DysfunctionAssociated Steatotic Liver Disease: A CrossSectional Study Mizuki Saito, Yoshihiro Shimazaki, Saori Yoshii, Tetsuhito Kojima Clinical and Experimental Dental Research .2026;[Epub] CrossRef Endoscopy for Metabolic Diseases Maria Valeria Matteo, Jana Kefah Ibrahim Hussein, Giorgio Carlino, Vincenzo Bove, Valerio Pontecorvi, Loredana Gualtieri, Martina De Siena, Mariachiara Di Vincenzo, Lorenzo Zileri Dal Verme, Daniele Salvi, Clarissa Ferrari, Cristiano Spada, Ivo Boskoski Journal of Clinical Medicine .2026

Mounjaro Approved For Both Diabetes And Weight Loss Treatments The dual effectiveness of Mounjaro in treating type 2 diabetes and promoting weight loss has made it a notable option in modern medicine
In a clinical trial of the Wegovy pill in people without diabetes, people taking a 25 mg dose lost about 6% of their body weight in three months
If you are comparing this to other peptides you may have used, the principle is identical to how lyophilized tirzepatide is stored
When this happens, your body responds by releasing GLP-1 (and CCK and PYY hormones), just like it would in response to food